Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | OSE 2101 |
Trade Name | |
Synonyms | EP-2101|Tedopi|OSE-2101|OSE2101|IDM2101 |
Drug Descriptions |
OSE 2101 is a cancer vaccine comprising HLA-A2+ restricted modified epitopes targeting CEA, ERBB2 (HER2), TP53, MAGE2, and MAGE3, which may result in activity of an immune response, leading to antitumor activity (Journal for ImmunoTherapy of Cancer 2021;9). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C26645 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Docetaxel + OSE 2101 | Docetaxel OSE 2101 | 0 | 1 |
Nivolumab + OSE 2101 | Nivolumab OSE 2101 | 0 | 2 |
OSE 2101 | OSE 2101 | 0 | 4 |
OSE 2101 + Pembrolizumab | OSE 2101 Pembrolizumab | 0 | 1 |